Category News

Airsupra Reduces Risk of Severe Asthma Exacerbations in Phase III BATURA Trial

AstraZeneca’s Airsupra (albuterol/budesonide) has demonstrated promising outcomes in the BATURA Phase IIIb trial, achieving its primary endpoint by significantly and meaningfully reducing the risk of severe asthma exacerbations when used as an as-needed rescue medication compared to albuterol alone. This…

Read MoreAirsupra Reduces Risk of Severe Asthma Exacerbations in Phase III BATURA Trial

GigaGen Secures U.S. BARDA Contract to Develop Antibody Therapies for Botulinum Neurotoxins and Biothreats

GigaGen Inc., a biotechnology firm specializing in innovative antibody treatments for immunodeficiencies, infectious diseases, and cancers resistant to checkpoint inhibitors, has announced a new contract awarded by the Biomedical Advanced Research and Development Authority (BARDA). BARDA, part of the U.S.…

Read MoreGigaGen Secures U.S. BARDA Contract to Develop Antibody Therapies for Botulinum Neurotoxins and Biothreats